BioCryst Stock Rises After White House Calls For Quicker Pace On Swine Flu Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Two Phase III trials are planned for a flu antiviral this year, but the company could be asked to provide supplies for U.S. emergency stockpile before approval.